Tenderwize
Retour à la recherche

Open House Discount Contracts 2026 - 14 - Lipegfilgrastim

Techniker Krankenkasse·Hamburg, Germany·Deadline Jun 29, 2028 · 673 days left·Open·Supplies
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 14 - Lipegfilgrastim

60/100

Score d'opportunité

PromisingLow complexity
SuppliesOpen
Pourquoi ce score ?

Opportunité

60 / 100

Complexité

20 / 100

Facteurs de risque

No estimated value or volume is provided, making it impossible to assess potential revenue.

The legal basis is unclear – the notice states it is not a public procurement under EU directives, but still follows an...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Strong opportunity

Faits clés

  • Supplies contract
  • 1 lot
  • Duration until Jun 2028
  • Supply of Lipegfilgrastim (pharmaceutical product, CPV 33600000) under discount agreements with TK and associated health insurers.
  • Nationwide coverage in Germany.
Afficher le résumé complet

Open House procedure by Techniker Krankenkasse (TK) for discount agreements on Lipegfilgrastim. Eligible pharmaceutical entrepreneurs can conclude contracts at any time during the 24-month term (July 2026 – June 2028). No estimated value or volumes are disclosed. Award criteria are not applied; all eligible participants are accepted. Submission is via email with qualified electronic signature or by post.

Risques

No estimated value or volume is provided, making it impossible to assess potential revenue.

The legal basis is unclear – the notice states it is not a public procurement under EU directives, but still follows an...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Must be a pharmaceutical entrepreneur (as per §4 Abs. 18 AMG) for the offered medicinal product.
  • Must have a valid marketing authorization in Germany or EEA.

Eligibility

  • Must provide self-declaration regarding authorization and reliability (no exclusion grounds).

Les exigences peuvent être incomplètes.

Critères d'attribution

Lot 1

No explicit award criteria – all eligible participants are accepted.

Acheteur

Localisation

Hamburg, DEU

Identifiant

992-80116-93

Activité

Health

Lots (1)

LOT-0001

Open House Discount Contracts 2026 - 14 - Lipegfilgrastim

Discount agreement for the active substance Lipegfilgrastim. Contract term up to 24 months starting 01 July 2026, ending no later than 30 June 2028. Contracts may be concluded at any time during the term.

SuppliesEU fundedElectronic submission

Localisation

DE600, Germany

Durée

Jun 2026 - Jun 2028

Catégorie

Pharmaceutical products

Critères d'attribution

No explicit award criteria – all eligible participants are accepted.

Date limite

Deadline Jun 29, 2028

Détails de la procédure

Date de publication
19 May 2026
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
345828-2026

Documents (1)

Document de consultation 1

Appels d'offres similaires

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3